GlassScriptPhysician profile
Ikami Sasa
NPI 1619460201
$925.54
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $413 · 2022: $195 · 2023: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $317.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $253.06 | 2021-2023 | Caplyta |
| Sunovion Pharmaceuticals INC. | $134.01 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $94.93 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.72 | 2021-2023 | Trintellix |
| Abbvie INC. | $64.25 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $63.85 | 2022-2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $63.08 | 2022-2023 | Jornay Pm |
| Adlon Therapeutics L.P. | $56.55 | 2021 | |
| Corium, LLC | $32.55 | 2023 | Azstarys |
| Eagle Pharmaceuticals, INC. | $19.39 | 2023 | |
| Tris Pharma INC | $16.50 | 2021 | |
| Eisai INC. | $13.69 | 2021 | |
| Neurocrine Biosciences, INC. | $13.38 | 2021 | |
| Allergan, INC. | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ikami Sasa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.